-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Liver cancer is the third leading cause of cancer-related deaths worldwide, with more than 780,000 people dying from the disease every year.
Liver cancer is the third leading cause of cancer-related deaths worldwide, with more than 780,000 people dying from the disease every year.
Previous studies have shown that HCC testing is still late, and only about 30-40% of American/European patients can be treated at the time of diagnosis.
This phase 1b/2 clinical study aims to evaluate the effect of tepotinib in patients with advanced hepatocellular carcinoma (aHCC) overexpressing MET treated with sorafenib in the United States/Europe.
This phase 1b/2 clinical study aims to evaluate the effect of tepotinib in patients with advanced hepatocellular carcinoma (aHCC) overexpressing MET treated with sorafenib in the United States/Europe.
Percentage of patients with 12-week progression-free survival
Percentage of patients with 12-week progression-free survivalIn Phase 1b of the trial, patients received 300 or 500 mg of Tepotinib daily.
The primary endpoints of the trial are dose-limiting toxicity (DLT; stage 1b) and 12-week progression-free survival (PFS; stage 2).
Kaplan-Meier curves of PFS, TTP and OS of patients in the phase 2 study
Kaplan-Meier curves of PFS, TTP and OS of patients in the phase 2 studyAll in all, the clinical trial results revealed that Tepotinib is well tolerated and has shown promising efficacy in RP2D (500mg) .
Tepotinib is well tolerated and has shown promising effects in RP2D (500mg).
org/10.
Leave a message here